

Table S2: Characteristics of Immunosuppressive Therapy Studies

Study Number	N	Urine protein, median (IQR)	Scr, mean (SD)	Events N (%)					Median FU, year
				ESRD	Doubling of Scr	Deaths	Composite	%	
IgA Nephropathy									
E21-1	34	1.0 (0.6, 2.7)	1.43 (0.36)	2	2	1	3	8.8	3.2
E21-2	73	1.6 (0.7, 3.2)	2.17 (0.71)	13	11	0	17	23.3	2.4
E21-3	97	2.1 (1.2, 3.5)	1.48 (0.48)	16	4	2	19	19.6	2.9
E21-4	29	2.3 (1.6, 3.3)	2.44 (1.07)	7	0	0	7	24.1	1.5
Lupus									
E22-1	83	2.5 (1.5, 3.8)	1.16 (0.64)	5	8	4	12	14.5	7.5
E22-2	62	3.9 (2.6, 7.0)	1.28 (0.64)	2	1	0	1	1.6	4.6
E22-3	83	4.4 (2.0, 8.2)	2.02 (1.24)	24	13	17	33	39.8	2.3
Membranous									
E23-1	11	4.5 (3.6, 9.0)	1.31 (0.57)	0	2	0	2	18.2	2.6
E23-2	76	4.8 (3.8, 7.9)	1.07 (0.27)	10	19	4	19	25.0	8.4
E23-3	10	5.2 (3.6, 6.8)	1.38 (0.57)	0	2	0	2	20.0	5.6
E23-4	76	5.4 (4.1, 7.8)	1.01 (0.28)	2	10	2	10	13.2	2.5
E23-5	91	5.5 (4.0, 8.7)	1.09 (0.42)	2	3	0	3	3.3	3.4
E23-6	31	5.6 (4.0, 8.1)	0.95 (0.29)	0	1	0	1	3.2	1.9
E23-7	48	7.3 (4.4, 9.7)	1.04 (0.23)	0	4	0	4	8.3	1.8

N, number; IQR, interquartile range; Scr, serum creatinine; SD, standard deviation; ESRD, end stage renal disease; FU, follow up. Units for urine protein are grams/day. One additional study was included in the description of the pooled dataset in the methods paper, which was removed due to no outcomes.

Note: Each study is referred by an alphanumeric code. Each letter refers to treatment comparisons, and each number refers to the individual studies. **A** is RAS (renin angiotensin system) Blockade vs. Control, **B** is RAS Blockade vs. CCB (calcium channel blocker), **C** is Intensive Blood Pressure **D** is Low protein diet, and **E** is Immunosuppressive therapy. For studies with multiple interventions, there will be multiple letter-number codes for that study. For example, AASK which had multiple interventions: RAS Blockage vs. placebo, RAS Blockade vs. CCB, and Blood pressure control. Its study number is 1, but it has three codes to indicate the specific treatment comparison: A1, B1 and C1.